Insider Transactions in Q3 2021 at Biomea Fusion, Inc. (BMEA)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 17
2021
|
Sotirios Stergiopoulos Director |
BUY
Open market or private purchase
|
Indirect |
34,658
+0.78%
|
$346,580
$10.96 P/Share
|
|
Sep 17
2021
|
A2 A Pharmaceuticals, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
34,658
+0.78%
|
$346,580
$10.96 P/Share
|
|
Aug 23
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
24,000
+9.51%
|
$312,000
$13.2 P/Share
|
|
Aug 23
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
24,000
+9.51%
|
$312,000
$13.2 P/Share
|
|
Aug 18
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.41%
|
$140,000
$10.77 P/Share
|
|
Aug 18
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.41%
|
$140,000
$10.77 P/Share
|
|
Aug 17
2021
|
Thomas Andrew Butler Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.85%
|
$140,000
$10.79 P/Share
|
|
Aug 17
2021
|
Rainer M Erdtmann President and COO |
BUY
Open market or private purchase
|
Indirect |
14,000
+6.85%
|
$140,000
$10.79 P/Share
|